Home › Funds › SUPERSTRING CAPITAL MANAGEMENT LP › SION
SUPERSTRING CAPITAL MANAGEMENT LP position in SION
SIONNA THERAPEUTICS INC · Health Care
SUPERSTRING CAPITAL MANAGEMENT LP reported holding 63,156 shares of SION (SIONNA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$2.8M, representing 1.75% of its reported portfolio and ranking #21 among its reported holdings. SUPERSTRING CAPITAL MANAGEMENT LP has disclosed SION holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SUPERSTRING CAPITAL MANAGEMENT LP's SION position evolved
SUPERSTRING CAPITAL MANAGEMENT LP first disclosed a stake in SION in Q4 2025 at 180,593 shares (US$7.4M). Across 3 filings, SUPERSTRING CAPITAL MANAGEMENT LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 63,156 shares valued at US$2.8M — a reduction of -77,868 shares quarter over quarter.. Notable position changes include a 55% trim in Q2 2026 (shares fell 88% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 180.59K | $7.43M | New |
| Q1 2026 | 141.02K | $5.65M | Reduce |
| Q2 2026 | 63.16K | $2.78M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SION and 13F data
SION (SIONNA THERAPEUTICS INC) is a Health Care company. 86 other funds we track also report a position in SION — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$435.7M), TPG GP A, LLC (US$285.7M), Atlas Venture Life Science Advisors, LLC (US$131.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SION
- RA CAPITAL MANAGEMENT, L.P. 9.91M sh · $435.72M · Q2 2026
- TPG GP A, LLC 6.49M sh · $285.71M · Q2 2026
- Atlas Venture Life Science Advisors, LLC 3.00M sh · $131.78M · Q2 2026
- ORBIMED ADVISORS LLC 2.56M sh · $112.43M · Q2 2026
- Enavate Sciences GP, LLC 2.48M sh · $109.01M · Q2 2026
- PERCEPTIVE ADVISORS LLC 905.00K sh · $39.81M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 680.92K sh · $29.95M · Q2 2026
- Siren, L.L.C. 610.51K sh · $26.86M · Q2 2026
- Casdin Capital 400.00K sh · $17.60M · Q2 2026
- Kalehua Capital Management LLC 197.07K sh · $8.67M · Q2 2026
- Sofinnova Investments, Inc. 144.43K sh · $6.35M · Q2 2026
- GordonMD Global Investments LP 136.00K sh · $5.98M · Q2 2026
More on SUPERSTRING CAPITAL MANAGEMENT LP
FAQ
How long has SUPERSTRING CAPITAL MANAGEMENT LP held SION?
SUPERSTRING CAPITAL MANAGEMENT LP has disclosed SION holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is SUPERSTRING CAPITAL MANAGEMENT LP's current position in SION?
As of Q2 2026, SUPERSTRING CAPITAL MANAGEMENT LP holds 63.16K shares of SION (SIONNA THERAPEUTICS INC), valued at $2.78M, representing 1.75% of its reported portfolio and ranking #21.
Has SUPERSTRING CAPITAL MANAGEMENT LP been buying or selling SION?
In the latest 13F filing (Q2 2026), SUPERSTRING CAPITAL MANAGEMENT LP reduced its position in SION.
Which other funds hold SION?
Other major institutional holders of SION include RA CAPITAL MANAGEMENT, L.P., TPG GP A, LLC, Atlas Venture Life Science Advisors, LLC, among 86 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.